The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Alopecia Areata, Atopic Dermatitis and Vitiligo (Global)
Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies. Pfizer’s GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the research gaps as outlined in the specific RFP.
The intent of this RFP is to support preclinical, clinical and outcomes research through a competitive grant program to increase medical knowledge in Alopecia Areata, Atopic Dermatitis, and/or Vitiligo. Please note that research focusing on Alopecia Areata and Atopic Dermatitis is of higher priority than Vitiligo at this time, and grants will be distributed accordingly.
Grant Application due date: August 16, 2021
Areas of Interest
Areas of Research Focus
• Alopecia Areata (AA) - Research proposals with the primary objective to increase the understanding of the role of the TEC family kinases and JAK3 kinase in the pathogenesis of AA, as well as the impact of their downregulation or inhibition.
• Atopic Dermatitis (AD) - Research and new insights into (1) the role of JAK-STAT pathway and inhibition in AD, (2) the various phenotypes/endotypes in AD, (3) factors influencing barrier function and repair, (4) the influence of the skin and gut microbiome in AD, (5) the factors influencing AD flares, and (6) the impact of Covid-19 on patients with AD.
• Vitiligo (Viti) - Research proposals with the primary objective to increase the understanding of the role of the TEC family kinases and JAK3 kinase in the pathogenesis of Viti, as well as the impact of their downregulation or inhibition.
Geographic Scope: Global (including U.S.A.)
• Only organizations are eligible to receive grants, not individuals or medical practice groups. • The applicant (PI) must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a degree in Pharmacy, Physiotherapy, or Social Work. • Applicant must be affiliated with a host institution
Individual projects requesting up to $175,000 (USD) will be considered. Pfizer anticipates awarding up to 15 grants.